National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Multiple Myeloma and Other Plasma Cell Neoplasms Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 07/24/2008



General Information About Multiple Myeloma and Other Plasma Cell Neoplasms






Stages of Multiple Myeloma and Other Plasma Cell Neoplasms







Refractory Multiple Myeloma and Other Plasma Cell Neoplasms






Treatment Option Overview






Treatment Options for Multiple Myeloma and Other Plasma Cell Neoplasms






To Learn More About Multiple Myeloma and Other Plasma Cell Neoplasms






Get More Information From NCI






Changes to This Summary (07/24/2008)






About PDQ



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
You CAN Quit Smoking Now!
Refractory Multiple Myeloma and Other Plasma Cell Neoplasms

Multiple myeloma and other plasma cell neoplasms are called refractory when the number of plasma cells continues to increase even though treatment is given.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov